Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:CBIONASDAQ:CYTXNASDAQ:MTEM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.75+2.5%$6.54$5.20▼$15.60$10.75M0.9110,987 shs10,966 shsCBIOCrescent Biopharma$16.90-6.1%$0.00$11.06▼$63.00$11.62M1.6264,475 shs109,227 shsCYTXCytori Therapeutics$0.37+16.4%$0.20$0.20▼$0.75$8.12M1.96915,302 shs170.35 million shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.09 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+2.50%+1.59%-10.16%-32.35%-60.63%CBIOCrescent Biopharma-6.11%+15.60%-97.80%-97.80%-97.80%CYTXCytori Therapeutics+68.45%+55.56%+5.35%-79.28%-80.79%MTEMMolecular Templates0.00%0.00%0.00%-75.00%-99.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.5189 of 5 stars3.25.00.00.03.31.71.3CBIOCrescent Biopharma3.1949 of 5 stars3.80.00.03.72.51.70.6CYTXCytori TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00769.57% UpsideCBIOCrescent Biopharma 3.67Strong Buy$25.0047.93% UpsideCYTXCytori Therapeutics 0.00N/AN/AN/AMTEMMolecular Templates 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYTX, BOLT, CBIO, and MTEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$22.005/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.44N/AN/A$29.89 per share0.19CBIOCrescent Biopharma$10K1,098.50N/AN/A$8.24 per share2.05CYTXCytori Therapeutics$3.67M2.21N/AN/A$0.35 per share1.05MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/A-665.56%-94.51%-59.07%8/12/2025 (Estimated)CBIOCrescent Biopharma-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/ACYTXCytori Therapeutics-$12.63MN/A0.00∞N/A-242.60%-272.70%-56.23%N/AMTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/ALatest CYTX, BOLT, CBIO, and MTEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CBIOCrescent BiopharmaN/A2.292.29CYTXCytori Therapeutics0.390.460.30MTEMMolecular TemplatesN/A1.561.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CBIOCrescent Biopharma75.19%CYTXCytori Therapeutics2.62%MTEMMolecular Templates95.47%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%CBIOCrescent Biopharma4.00%CYTXCytori Therapeutics0.66%MTEMMolecular Templates13.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableCBIOCrescent Biopharma26650,000619,000No DataCYTXCytori Therapeutics3722.16 millionN/ANot OptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataCYTX, BOLT, CBIO, and MTEM HeadlinesRecent News About These CompaniesMolecular Templates enters bankruptcy, secures DIP financingApril 26, 2025 | investing.comWhat’s Fueling Molecular Templates Inc (MTEM) Stock’s -91.30% Loss Below Its 200-Day SMA?December 26, 2024 | bovnews.comBMolecular Templates Inc (MTEM) Stock: More Resilient Than It AppearsDecember 23, 2024 | bovnews.comBNasdaq to file Form 25-NSE with SEC to delist Molecular TemplatesDecember 20, 2024 | markets.businessinsider.comMolecular Templates, Inc. Faces Delisting from Nasdaq Due to Compliance IssuesDecember 19, 2024 | quiverquant.comQMolecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesDecember 19, 2024 | globenewswire.comMolecular Templates Inc (MTEM) Stock Settles at $0.42: What’s Contributing to This Price Point?December 10, 2024 | bovnews.comBMolecular Templates Inc (MTEM) Stock Price Reaches $0.34: What Factors Are Influencing This Level?December 5, 2024 | bovnews.comBMolecular Templates Announces Key Leadership TransitionDecember 4, 2024 | markets.businessinsider.comMolecular Templates, Inc. Receives Nasdaq Deficiency Notification for Reporting and Bid Price ComplianceDecember 2, 2024 | quiverquant.comQMolecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsDecember 2, 2024 | globenewswire.comMolecular Templates Inc (MTEM) Stock Settles at $0.37: What’s Contributing to This Price Point?November 29, 2024 | bovnews.comBWhy Did BofA Securities Give Molecular Templates Inc (MTEM) Stock Buy Rating?November 27, 2024 | bovnews.comBMolecular Templates Inc (MTEM) Stock Sees Market Value Hit $2.21 million: What Are the Implications?November 26, 2024 | bovnews.comBMolecular Templates Inc (MTEM) Stock: More Strategic Than Meets the EyeNovember 23, 2024 | bovnews.comBTarget N. V. Biotech Sells 1,279,820 Shares of Molecular Templates, Inc. (NASDAQ:MTEM) StockNovember 19, 2024 | insidertrades.comWhy Did Molecular Templates Inc (MTEM) Stock See -69.97% Plunge in the Last 90 Days?November 19, 2024 | bovnews.comBMolecular Templates Inc (MTEM) Stock: Surpassing Expectations in the Market?November 16, 2024 | bovnews.comB“Astonishing” – Scientists Unveil First Blueprint of the Most Complex Molecular Machine in Human BiologyNovember 10, 2024 | scitechdaily.comSWhy Did Molecular Templates Inc (MTEM) Stock See -44.44% Plunge in the Last 90 Days?October 22, 2024 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTX, BOLT, CBIO, and MTEM Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.75 +0.14 (+2.50%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$5.90 +0.15 (+2.52%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Crescent Biopharma NASDAQ:CBIO$16.90 -1.10 (-6.11%) As of 06/26/2025 04:00 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Cytori Therapeutics NASDAQ:CYTXCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
